Vaxart has developed a platform technology that will let almost any vaccine be delivered orally. Our initial applications include Avian Influenza, annual influenza, second-generation oral versions of existing vaccines, and unmet needs. The company is currently testing an avian flu vaccine in animal models and is working toward a clinical trial in 2010.

Advantages of the VAXART^® Vaccine Platform

• Oral delivery is strongly preferred by care providers and patients. 
  
  
• New vaccines can be created very quickly to protect against new circulating avian flu strains, other emerging pathogens, or biodefense threats.
  
  
• Vaxart uses efficient and standardized manufacturing methods, with essentially the same process for every Vaxart vaccine.
  
  
• VAXART vaccines retain potency for more than a month at room temperature, potentially allowing final distribution without refrigeration or the need for administration by trained medical staff.
  
  
• VAXART vaccines generate antigen-specific killer T-cell and IgA antibody responses, as well as IgG antibody responses.
  
  
• Oral vaccination with live adenovirus (to prevent respiratory adenovirus infection) has an excellent safety record in millions of subjects.

News:

June 2011:  Vaxart initiates an oral vaccine clinical trial.  Read more...

March 2010:  Vaxart announces completion of Series B financing.  Read more... 

September 2009:  NIAID divison of NIH awards $2.8 million SBIR Phase II grant to Vaxart to continue to develop oral vaccine platform.  Read more...

June 2009:  Vaxart demonstrates strong immune responses against H1N1 (Swine Flu) in animal studies.

May 2009: Vaxart initiates animal testing of candidate H1N1 vaccine.  Read more...

See our VAXART and Swine Flu Fact Sheet.  Vaxart was recently featured in The Wall Street Journal Venture Dispatch, Discover Magazine, KNTV NBC-11, KRON-TV, and a front page story in the San Jose Mercury News.

April 2009: Vaxart presents at  BayBio2009 conference in South San Francisco and 11th Annual C21 BioVentures conference in Napa.

October 2008: Vaxart reports demonstration of oral vaccine efficacy against lethal avian flu challenge in ferret and mouse models, at Modern Mucosal Vaccines Adjuvants & Microbicides conference in Portugal.  Read more...

June 2008: Vaxart presents at BIO International Conference in San Diego.

March 2008: Robert Fildes, former President of Biogen and CEO of Cetus, joins Vaxart Board as Chairman.  Read more...

January 2008: Vaxart profiled in Startup (Windhover publications).

November 2007: Vaxart (fka West Coast Biologicals) Completes Series A Financing. Read more...

November 2007: NIAID division of NIH awards $600,000 SBIR grant to Vaxart to develop oral vaccine platform.

April 2006: West Coast Biologicals is a finalist in the 2006 Global Life Sciences Innovation Accelerator Competition at UCSF.